Millipore Shares Rise on Upgrade | GenomeWeb

NEW YORK (Genomeweb News) – Shares of Millipore were up 4 percent at $69.02 in afternoon trade on the New York Stock Exchange after an upgrade to its rating by investment bank Leerink Swann.

The bank raised its rating on Millipore to "outperform" from "market perform." Analyst Isaac Ro said that the change was due to "improving fundamentals and execution."

Millipore "should benefit from exposure to a number of themes that include cell-based H1N1 vaccine production, an improving biologics pipeline, recent product launches, and stimulus funding," wrote Ro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.